Phase III trial of cyclophosphamide, epirubicin, fluorouracil (CEF) versus cyclophosphamide, mitoxantrone, fluorouracil (CNF) in women with metastatic breast cancer

Breast Cancer Research and Treatment

Volumn 58, Issue 2, 1999, Pages 141-150

  Esteban, E ^a   Lacave, A J ^a   Fernandez J L ^a   Corral, N ^a   Buesa, J M ^a   Estrada, E ^a   Palacio, I ^a   Vieitez, J M ^a   Muniz I ^a   Alvarez, E ^a  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

Author keywords

Epirubicin; Metastatic breast cancer; Mitoxantrone

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; MITOXANTRONE;

ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DISEASE COURSE; DRUG ACTIVITY; DRUG RESPONSE; DRUG SAFETY; FEMALE; HEMATOLOGY; HUMAN; LEUKOPENIA; MAJOR CLINICAL STUDY; METASTASIS; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL TIME; THROMBOCYTOPENIA;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CYCLOPHOSPHAMIDE; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; ELECTROCARDIOGRAPHY; EPIRUBICIN; FEMALE; FLUOROURACIL; HUMANS; KARNOFSKY PERFORMANCE STATUS; MIDDLE AGED; MITOXANTRONE; PROSPECTIVE STUDIES; SPAIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033427002     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1006387801960     Document Type: Article

References (31)

1. 1. Smalley RV, Carpenter J, Bartolucci A, et al.: A comparison of cyclophosphamide, adriamycin, 5-fluorouracil (CAF) and cyclophosphamide, methotrexate , 5-fluorouracil, vineristine, prednisone (CMFVP) in patients with metastatic breast cancer. Cancer 40: 625-632, 1977
2. 2. Bull JM, Tormey DC, Li S, et al.: A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer 41: 1649-1657, 1978
3. 3. Falkson G, Gelman R, Tormey DC, et al.: The Eastern Cooperative Oncology Group experience with cyclophosphamide, Adriamycin, and 5-fluorouracil (CAF) in patients with metastatic breast cancer. Cancer 56: 219-224, 1985
4. 4. Brambilla C, Rossi A, Bonfante V, et al.: Phase II study of doxorubicin versus epirubicin in advanced breast cancer. Cancer Treat Rep 70: 261-266, 1986
5. 5. Hayat M, Chauvergne J, Fargeot P, et al.: Phase III Chemotherapy comparing FAC versus FEC in advanced breast cancer: Preliminary results. Proc Am Sot Clin Oncol: C-460, 1984
6. 6. Intini C, Zingali G, de Micheli P, et al.: FEC versus FAC in advanced breast cancer. Results of an Italian cooperative study. Cancer Chemother Pharmacol 18 (Suppl 1): A38, 149, 1986
7. 7. Bennett JM, Muss HB, Doroshow JH, et al.: A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in therapy of metastatic breast carcinoma. J Clin Oncol 6: 1611-1620, 1988
8. 8. Henderson IC, Wolff S, Allegra J, et al.: Mitoxantrone versus doxorubicin in advanced breast cancer: a randomized trial in 220 patients. Third European Conference on Clinical Oncology and Cancer Nursing. ECCO 3. Novantrone Satellite Symposium. Stockholm, 19 June, 1985, Abstract Book, 4
9. 9. Neidhart JA, Gochnour D, Roach R, et al.: A comparison of mitoxantrone and doxorubicin in breast cancer. J Clin Oncol 4: 672-677, 1986
10. 10. Engelsman E, Rubens RD, Klijn JGM, et al.: Comparison of "classical CMF" with three-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: an EORTC study (Trial 10808). 4th EORTC Breast Cancer Working Conference, 30 June - 3 July, 1987
11. 11. Alexander J, Daimak N, Berber HJ, et al.: Serial assessement of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300: 278-283, 1979
12. 12. Miller AB, Hoogstraten B, Staquet M, et al.: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
13. 13. Hayward JL, Carbone PP, Heuson JC, et al.: Assessment of response to therapy in advanced breast cancer. Eur J Cancer Cli Oncol 13: 89-94, 1977
14. 14. Cochran WG: The chi-square test of goodness of fit. Ann Math Stat 23: 315-345, 1952
15. 15. Winer BJ: Statistical Principles in Experimental Design. McGraw-Hill, London, England, 1970
16. 16. Mehta CR, Patel NR: A network algorithm for performing Fisher's exact test in r × c contingency tables. J Am Stat Assoc 78: 427-434, 1983
17. 17. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958
18. 2/E in the log-rank test for survival data or tumor incidence data. Biometrics 29: 579-584, 1973
19. 19. Allegra JC, Woodcock T, Woolf S, et al.: A randomized trial comparing mitoxantrone with doxorubicin in patients with stage IV breast cancer. Invest New Drugs 3: 153-161, 1985
20. 20. Henderson IC, Allegra JC, Woodcock T, et al.: Randomized clinical trial comparing mitoxantrone with doxorubicin in previously treated patients with metastatic breast cancer. J Clin Oncol 7: 560-571, 1989
21. 21. Cowan JD, Neidhart J, McClude S, et al.: Randomized trial of doxorubicin, bisantrene, and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J Natl Cancer Inst 83: 1077-1084, 1991
22. 22. Lawton PA, Spittle MF, Ostrowski MJ, et al.: A comparison of doxorubicin, epirubicin and mitozantrone as single agents in advanced breast carcinoma. Clin Oncol (R. Coll Radiol) 5(2): 80-84, 1993
23. 23. Follezou JY, Palangie T, Feuilhade F, et al.: Essai randomise comparant la mitoxantrone a l'adriamycine dans les cancers du sein evolves. La presse medicale 16(16): 765-768, 1987
24. 24. Periti P, Pannuti F, Della Cuna GR, et al.: Combination chemotherapy with cyclophosphamide, fluorouracil, and either epirubicin or mitoxantrone: a comparative randomized multicenter study in metastatic breast cancer. Cancer Invest 9: 249-255, 1991
25. 25. Taguchi T, Sakai K, Terasawa T, et al.: Result of clinical trials with a CAF (cyclophosphamide, adriamycin, and 5-fluorouracil) regimen versus a CMITF (cyclophosphamide, mitoxantrone and 5-fluorouracil) regimen in advanced relapsed breast cancer. Jpn J Cancer Chemother 13: 2820-2828, 1986
26. 26. Buyukunal E, Derman U, Serdengecti S, et al.: A clinical trial of mitoxantrone versus doxorubicin in combination chemotherapy for metastatic breast cancer. Chemioterapia 6: 377-379, 1987
27. 27. Heidemann E, Steinke B, Hartlapp J, et al.: Randomized clinical trial comparing mitoxantrone with epirubicin and with doxorubicin, each combined with cyclophosphamide in the first-line treatment of patients with metastatic breast cancer. Onkologie 13: 24-27, 1990
28. 28. Alonso MC, Tabernero JM, Ojeda B, et al.: A phase III randomized trial of cyclophosphamide, mitoxantrone, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in patients with metastatic breast cancer. Breast Cancer Res Treat 34: 15-24, 1995
29. 29. Stewart DJ, Evans WK, Shepherd FA, et al.: Cyclophosphamide and fluorouracil combined with mitoxantrone versus doxorubicin for breast cancer: superiority of doxorubicin. J Clin Oncol 15: 1897-1905, 1997
30. 30. Hausmaninger H, Lehnert M, Steger G, et al.: Vindesine-epirubicin versus vindesine-mitoxantrone in metastatic breast cancer. Onkologie 12: 225-229, 1989
31. 31. Rahman ZU, Frye DK, Smith TL, et al.: Results and long term followup for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy. Cancer 85: 104-111, 1999